Navigation Links
Medco Tops Fortune's List of 'America's Most Admired' Companies in its Industry
Date:3/6/2008

Medco listed No. 1 Among Health Care: Pharmacy and Other Services; No. 1 in People Management; Runner-up to Berkshire-Hathaway as Long-Term Investment;

No. 3 for Innovation

FRANKLIN LAKES, N.J., March 6 /PRNewswire-FirstCall/ -- Medco Health Solutions, Inc. (NYSE: MHS), captured the No. 1 position within the Health Care: Pharmacy and Other Services sector on Fortune's America's Most Admired Companies List. In addition, of all companies surveyed, Medco was ranked No. 1 in People Management. Medco was listed as No. 2 among all companies as "Most Admired: Long-Term Investment" -- second only to Berkshire Hathaway; and third in the U.S. based on "Innovation," trailing Apple and Nike.

"To be ranked highest among our industry peers is a tremendous honor. To join some of the world's most revered companies across all industries -- second only to the legendary Berkshire Hathaway as a quality investment and in the same league as Apple and Nike for innovation -- underscores the value Medco delivers to the marketplace in improving clinical and financial outcomes for the millions of Americans we serve every day," said David B. Snow Jr., Medco Chairman and CEO.

Fortune, in partnership with the Hay Group, surveyed 622 companies across 64 industry sectors. To create the industry lists, executives, directors and analysts were asked to rate companies in their own industry on eight criteria, from investment value to social responsibility. Results are featured in the March 17th issue of Fortune magazine.

According to the Fortune survey, Medco received several industry and national honors:
-- No. 1 Most-Admired: "Health Care: Pharmacy and Other Services"

category -- with the industry's highest rank in each of eight

attributes: innovation, people management, use of corporate assets,

social responsibility, quality of management, financial soundness,

long-term investment and quality of products/services.

-- No. 1 nationwide in People Management

-- No. 2 nationwide for Long-Term Investment, following

Berkshire-Hathaway.

-- No. 3 nationwide in Innovation, following Apple and Nike.

-- No. 3 nationwide for Quality of Products and Services, following

Anheuser-Busch and Nordstrom.

-- No. 6 nationwide for Financial Soundness.

-- No. 7 nationwide in Social Responsibility.

-- No. 10 nationwide for Use of Corporate assets.

-- Among the most admired in New Jersey.

Continued Snow: "Innovation and quality describe not only our company, but the values of our people who are dedicated to pushing the frontier of pharmacy to improve clinical and financial outcomes -- ensuring quality care remains affordable and accessible."

Medco is redefining pharmacy practice by employing hundreds of trained specialist pharmacists to help improve the quality of care for patients with chronic and complex conditions. These pharmacists are better positioned to identify safety issues and consult more effectively with doctors to improve patient care and help lower overall health care costs. The specialist pharmacists work within the Medco Therapeutic Resource Centers(R), with specific centers located nationwide focused on conditions that include diabetes, oncology, arthritis, high blood pressure, high cholesterol and neurology/psychology.

About Medco

Medco Health Solutions, Inc., (NYSE: MHS) is the nation's leading pharmacy benefit manager based on its 2007 total net revenues of more than $44 billion. Medco's prescription drug benefit programs, covering one in five Americans, are designed to drive down the cost of pharmacy health care for private and public employers, health plans, labor unions and government agencies of all sizes, and for individuals served by the Medicare Part D Prescription Drug Program. Medco, the world's most advanced pharmacy(TM), is positioned to serve the unique needs of patients with chronic and complex conditions through its Medco Therapeutic Resource Centers(R); its diabetes pharmacy care practice, Liberty Medical; and its specialty pharmacy operation, Accredo Health Group, Inc. Medco is the highest-ranked independent pharmacy benefit manager on the 2007 Fortune 500 list. On the Net: http://www.medco.com.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward- looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the risks and uncertainties that affect our business, particularly those mentioned in the Risk Factors section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Medco Health Solutions, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MedCom USA Signs Southwood Medical Marketing to Distribute MedCom System
2. Medco Full-Year and Fourth-Quarter Earnings Results Exceed High End of Company Expectations
3. Medco Launches Medicare Part D Initiative to Promote ePrescribing
4. Medco Announces Date for Fourth-Quarter and Full-Year 2007 Financial Results
5. Medcos Specialized Pharmacists, Safety Programs Gain Therapy Management Accreditation
6. Medco CEO Reiterates Guidance, Positive Outlook for 2008
7. MedcomSoft Receives 2007s "Best in KLAS" EMR Ranking (1-5 Physicians)
8. MedcomSoft appoints former U.S. presidential health advisor, James Haveman, to health Care advisory board
9. URAC Names Medco as a Finalist in First-ever Best Practices in Consumer Empowerment and Protection Awards
10. Medco Announces Two-For-One Stock Split
11. Medco CEO to Present at the Merrill Lynch & Co., Inc. 2007 Health Services Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, the game-changing dual ... opening of the Sober College Robert Pfeifer Memorial Learning Center at its location ... was attended by an overwhelming amount of alumni, family, colleagues and friends of ...
(Date:12/9/2016)... ... ... "I had a terrible time trying to get my grandson to use his ... had a more child-friendly design, then children would be more likely to look forward ... avoid the need to deliver medication via a nebulizer mask. The design will not ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Company LLC, announced the first national #QuackGivesBack campaign which supported local breast ... was our first franchise-wide Quack Gives Back initiative, and we’re very ...
(Date:12/8/2016)... ... 08, 2016 , ... With the increasing demand for dental implants, the National ... campaign to inform dentists and patients about the safety issues related to dental restorations. ... in the U.S. is projected to reach $6.4 billion in 2018 with more than ...
(Date:12/8/2016)... N.J. (PRWEB) , ... December 08, 2016 , ... ... delivery technologies and development solutions for drugs, biologics and consumer health products, today ... PSCI was set up in 2006 as a non-profit organization to unite pharmaceutical ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016 Allergy Diagnostics Market: Scope and ... that are used to determine the presence of ... drugs etc. in the samples by determining the ... The report on global allergy diagnostics market, analyzes ... The report consists of an executive summary that ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Dec. 8, 2016  Valeant Pharmaceuticals International, Inc. ... ("Valeant") today announced positive results from a Phase ... assess the safety and efficacy of IDP-118 (halobetasol ... plaque psoriasis. Within the Phase ... to severe psoriasis, IDP-118 showed statistical significance to ...
Breaking Medicine Technology: